Baidu
map

疫情常态化防控,PCR实验室建设的挑战和亟需解决的问题

2020-06-19 网络 网络

为进一步提高医疗机构新冠肺炎防控和救治能力,巩固来之不易的防控成果,实现“外防输入、内防反弹”目标,国务院接连发布《关于进一步巩固成果提高医疗机构肺炎防控和救治能力的通知》、《关于进一步做好疫情期间新

中国疫情防控正在步入一个新阶段——“常态化”。
 
但,常态化≠疫情结束!
 
为进一步提高医疗机构新冠肺炎防控和救治能力,巩固来之不易的防控成果,实现“外防输入、内防反弹”目标,国务院接连发布《关于进一步巩固成果提高医疗机构肺炎防控和救治能力的通知》、《关于进一步做好疫情期间新冠病毒检测有关工作的通知》、《关于做好疫情常态化防控下新冠病毒核酸检测质量控制工作的通知》等通告。
 
要求各地采取措施加强医疗机构实验室建设,对陆路边境口岸等地区优先支持建设,提高检测能力。并指出防控要常态化、扩大化、要进一步加强实验室建设,扩大新冠病毒核酸检测范围,提高新冠病毒检测能力,保证核酸检测质量。
 
进入常态化防疫阶段,提高医疗机构的长期防疫能力,巩固来之不易的防疫成果,仍是当下各医疗机构和从业人员关注的重点。
 
那么如何快速进行实验室建设及质量保证?
新型冠状病毒核酸检测开展有哪些技术要点?
实验室管理上有哪些经验值得借鉴与分享?
 
基于疫情防控要求以及一线老师需要,促进一线检验人员加深对临床基因扩增实验室的建设和日常管理的理解。艾康生物特邀大咖专家浙江大学附属第二医院检验科主任陶志华教授、天津医科大学总医院空港医院检验科主任袁玉华教授及杭州艾迪康医学检验中心PCR实验室丁进龙经理做客直播。
 
本次直播将直击当下困扰,共同就“临床基因扩增实验室建设与质量管理”等相关热点问题进行经验分享和探讨,欢迎届时扫码进入直播间,邀您共同参与。




扫描上方二维码或点击左下角“阅读原文”进入直播。
 
06月19日(周五)14:00-16:00
携手大咖邀您共讨
「临床基因扩增实验室建设与质量管理」
 
参与直播,更有惊喜好礼相送
 
敬请期待!
 
艾康生物技术(杭州)有限公司
 
艾康生物技术(杭州)有限公司成立于1995年,依托中美两地生物技术研发实力、严苛的质量控制体系、全球化的销售合作策略,服务全球人类健康领域。公司致力于生物诊断行业的原物料开发、诊断产品研发、生产、销售和一体化服务,为全球客户提供医疗领域的整体解决方案。
 
作为生物诊断领域的排头兵,艾康生物已成功开发便携血糖检测、尿液分析系统、血液分析系统、PCR检测系统、免疫检测系统等多个平台产品。公司一直坚持质量体系建设,保持以出色的成绩陆续通过美国、中国 、欧盟、巴西、韩国等食品药品监督审核,并获得当地市场准入,产品品质已得到148个国家和地区的认可。在“立足本土”的全球化战略下,公司在中国、美国、墨西哥地区逐步实现产业升级,为当地及全球的诊断需求提供快速服务。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976829, encodeId=6b5319e68292b, content=<a href='/topic/show?id=19ca4609398' target=_blank style='color:#2F92EE;'>#实验室建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46093, encryptionId=19ca4609398, topicName=实验室建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Sep 18 07:34:33 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659770, encodeId=9d661659e7069, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Mon Aug 03 04:34:33 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805118, encodeId=cb7f80511889, content=做好自己,保护别人也保护自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33ee5216569, createdName=1476f000m96暂无昵称, createdTime=Wed Jul 29 22:32:32 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419447, encodeId=47ba141944eb8, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sat Jun 20 16:34:33 CST 2020, time=2020-06-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1976829, encodeId=6b5319e68292b, content=<a href='/topic/show?id=19ca4609398' target=_blank style='color:#2F92EE;'>#实验室建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46093, encryptionId=19ca4609398, topicName=实验室建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Sep 18 07:34:33 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659770, encodeId=9d661659e7069, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Mon Aug 03 04:34:33 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805118, encodeId=cb7f80511889, content=做好自己,保护别人也保护自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33ee5216569, createdName=1476f000m96暂无昵称, createdTime=Wed Jul 29 22:32:32 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419447, encodeId=47ba141944eb8, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sat Jun 20 16:34:33 CST 2020, time=2020-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1976829, encodeId=6b5319e68292b, content=<a href='/topic/show?id=19ca4609398' target=_blank style='color:#2F92EE;'>#实验室建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46093, encryptionId=19ca4609398, topicName=实验室建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Sep 18 07:34:33 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659770, encodeId=9d661659e7069, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Mon Aug 03 04:34:33 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805118, encodeId=cb7f80511889, content=做好自己,保护别人也保护自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33ee5216569, createdName=1476f000m96暂无昵称, createdTime=Wed Jul 29 22:32:32 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419447, encodeId=47ba141944eb8, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sat Jun 20 16:34:33 CST 2020, time=2020-06-20, status=1, ipAttribution=)]
    2020-07-29 1476f000m96暂无昵称

    做好自己,保护别人也保护自己

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1976829, encodeId=6b5319e68292b, content=<a href='/topic/show?id=19ca4609398' target=_blank style='color:#2F92EE;'>#实验室建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46093, encryptionId=19ca4609398, topicName=实验室建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Sep 18 07:34:33 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659770, encodeId=9d661659e7069, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Mon Aug 03 04:34:33 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805118, encodeId=cb7f80511889, content=做好自己,保护别人也保护自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33ee5216569, createdName=1476f000m96暂无昵称, createdTime=Wed Jul 29 22:32:32 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419447, encodeId=47ba141944eb8, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sat Jun 20 16:34:33 CST 2020, time=2020-06-20, status=1, ipAttribution=)]
    2020-06-20 Tommy1950
Baidu
map
Baidu
map
Baidu
map